Stephen Oesterle joins the Novo Holdings Advisory Group

Novo Holdings is pleased to announce the appointment of Dr Stephen Oesterle to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments.

Kasim Kutay, CEO of Novo Holdings, said: “With his extensive experience in the medical technology industry, both at executive level and as a corporate advisor and venture partner, Stephen possesses strategic know-how that will be important to the work of the NAG. I very much look forward to working with Stephen.”

Between 2002 and 2015, Stephen was a member of Medtronic’s Executive Committee, serving as Senior Vice President for Medicine and Technology. In this role, he contributed to the company’s business development, operating plans and long-term strategies. In addition, Stephen had corporate oversight of Medtronic’s technology R&D, developing and leading collaborative relationships with technical universities, high tech corporations and medical device start-ups.

Prior to this, Stephen served as Associate Professor of Medicine at the Harvard University Medical School and as Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. As a teacher and innovator in the field of cardiac catheterization, he also developed and directed interventional cardiology programmes at Good Samaritan Hospital, Los Angeles, as well as at the universities of Georgetown and Stanford.

Stephen is independent director on several public and private boards in the USA, Switzerland, Germany and China.

Stephen Oesterle said: “I feel honoured to join the Novo Holdings Advisory Group. It is a great opportunity to be able to leverage my know-how and experience and contribute to Novo Holdings’ important mission of generating attractive financial returns to improve people’s health and the sustainability of society and the planet.”

About Stephen Oesterle
US citizen

Board positions
Stephen serves on a wide range of boards, including Baxter International (NYSE), Peijia Medical (Shanghai) Paragon 28 (NYSE), Private equity backed SHL Medical AG (Zürich) and  CeramTec (Germany) and venture backed Alcyone Therapeutics and Anuncia.

Career
2021 –               Venture Partner, Cathay Capital and CBC Group

2015 –               Advisor to various private equity firms

2015- 2021       Venture Partner, New Enterprise Associates

2002 – 2015    Medtronic, Plc. Sr. Vice President, Medicine & Technology

1998 – 2002    Associate Professor of Medicine, Director, Invasive Cardiology Services, Harvard Medical School, Massachusetts General Hospital

1992 – 1998     Associate Professor of Medicine, Director, Cardiac Catheterization and Coronary Intervention Laboratories, Stanford University Medical Center

1991 – 1992      Associate Professor of Medicine, Director, Cardiac Catheterization and Coronary Intervention Laboratories, Georgetown University Medical Center

1986 – 1992     Director, Cardiac Catheterization and Coronary Intervention Laboratories, Good Samaritan Hospital, Los Angeles

Education
Stephen is a summa cum laude graduate of Harvard University and received his doctorate in medicine from Yale University. He completed his internship and residency at Massachusetts General Hospital and served a fellowship in interventional cardiology at Stanford.

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
www.novonordiskfonden.dk/en